Kymera reports positive KT-474 Phase 1 data; Sanofi advances to Phase 2; oncology programs show target knockdown

Kymera Therapeutics, Inc.

KT-474 achieved >90% IRAK4 degradation in blood and skin; cytokine inhibition up to 98% in AD and 84% in HS; no serious AEs.
Sanofi committed to Phase 2 trials for KT-474 in HS and AD, with first study starting in 2023.
KT-413 (IRAKIMiD) showed up to 100% Ikaros/Aiolos knockdown and 40% IRAK4 knockdown at dose level 2; no DLTs.
KT-333 (STAT3) showed mean 66% STAT3 degradation (up to 86%) in PBMC at dose level 1; dose level 2 enrolling.
FDA cleared IND for KT-253 (MDM2 degrader); Phase 1 planned for early 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.